{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:37:04Z","timestamp":1777876624285,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Taiho Oncology, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Trifluridine\/tipiracil plus bevacizumab (FTD\/TPI\u2009+\u2009BEV) has shown efficacy and tolerability in refractory metastatic colorectal cancer (mCRC). Because randomized controlled trial (RCT) data comparing FTD\/TPI\u2009+\u2009BEV with FTD\/TPI are lacking, this meta-analysis evaluated outcomes with both regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Methods:<\/jats:title>\n                    <jats:p>Electronic databases, congress proceedings (past 3\u2009years), trial registries, systematic review bibliographies, gray literature, and guidelines through June 2021 were searched for RCTs, non-RCTs, and prospective observational studies involving &gt;20 previously treated patients with mCRC receiving FTD\/TPI\u2009+\u2009BEV or FTD\/TPI. Absolute and relative disease control rate (DCR), progression-free survival (PFS), overall survival (OS), adverse event (AE) rates, and discontinuation rates due to AEs were evaluated using fixed-effects and random-effects models. Study quality, heterogeneity, and publication bias were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In all, 29 of 875 screened publications were selected (26 studies: 5 RCTs, 11 non-RCTs, and 10 prospective observational studies). One RCT compared FTD\/TPI\u2009+\u2009BEV with FTD\/TPI. FTD\/TPI\u2009+\u2009BEV versus FTD\/TPI had a higher absolute DCR [64% (6 studies; n\u2009=\u2009289) versus 43% (10 studies; n\u2009=\u20092809)], median PFS [4.2 (5 studies; n\u2009=\u2009244) versus 2.6 (6 studies; n\u2009=\u20091781) months], 12-month PFS [9% (5 studies; n\u2009=\u2009244) versus 3% (6 studies; n\u2009=\u20091781)], median OS [9.8 (5 studies; n\u2009=\u2009244) versus 8.1 (6 studies; n\u2009=\u20091814) months], and 12-month OS [38% (5 studies; n\u2009=\u2009244) versus 32% (6 studies; n\u2009=\u20091814)]. Grade \u2a7e3 febrile neutropenia, asthenia\/fatigue, diarrhea, nausea, and vomiting rates were similar (1%\u20137%). Grade \u2a7e3 neutropenia rate was higher with FTD\/TPI\u2009+\u2009BEV than with FTD\/TPI [43% (6 studies; n\u2009=\u2009294) versus 29% (12 studies; n\u2009=\u20097139)]. Discontinuation rates due to AEs were similar [8% (5 studies; n\u2009=\u2009244) and 7% (10 studies; n\u2009=\u20093724)]. Low study quality, heterogeneity, and\/or publication bias were detected in certain instances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite fewer patients treated with the combination, this meta-analysis consistently suggested that FTD\/TPI\u2009+\u2009BEV provides benefits over FTD\/TPI in refractory mCRC and has similar safety, except for more frequent grade \u2a7e3 neutropenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359221146137","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:11:53Z","timestamp":1674274313000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Trifluridine\/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis"],"prefix":"10.1177","volume":"15","author":[{"given":"Takayuki","family":"Yoshino","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"H\u00f4pital Europ\u00e9en Georges-Pompidou, Universit\u00e9 Paris-Cit\u00e9, SIRIC CARPEM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-0586","authenticated-orcid":false,"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8777-9456","authenticated-orcid":false,"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"SmartAnalyst India Pvt Ltd, Gurugram, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"bibr1-17588359221146137","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-17588359221146137","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colorectal cancer, https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html (2022, accessed 18 February 2022)."},{"key":"bibr3-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2673"},{"key":"bibr4-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"bibr5-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106"},{"key":"bibr6-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx738"},{"key":"bibr7-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70345-5"},{"key":"bibr8-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"bibr9-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.06.001"},{"key":"bibr10-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.009"},{"key":"bibr11-17588359221146137","first-page":"2135","volume":"33","author":"Tsukihara H","year":"2015","journal-title":"Oncol Rep"},{"key":"bibr12-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30827-7"},{"key":"bibr13-17588359221146137","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n                      \u00ae\n                      ) for Colon Cancer: V.1.2022.\n                      \u00a9\n                      National Comprehensive Cancer Network, Inc. All rights reserved. (2022, accessed June 7, 2022)."},{"key":"bibr14-17588359221146137","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n                      \u00ae\n                      ) for Rectal Cancer: V.1.2022.\n                      \u00a9\n                      National Comprehensive Cancer Network, Inc. All rights reserved (2022, accessed June 7, 2022)."},{"key":"bibr15-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.04.004"},{"key":"bibr16-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.12"},{"key":"bibr17-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"bibr18-17588359221146137","unstructured":"Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. www.handbook.cochrane.org (2011, accessed 28 February 2022)."},{"key":"bibr19-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377"},{"key":"bibr20-17588359221146137","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2013, accessed 28 February 2022)."},{"key":"bibr21-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"bibr22-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"bibr23-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386"},{"key":"bibr24-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7129.469"},{"key":"bibr25-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"bibr26-17588359221146137","first-page":"1","volume":"39","author":"Karthaus M","year":"2016","journal-title":"Oncol Res Treat"},{"key":"bibr27-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000261"},{"key":"bibr28-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245"},{"key":"bibr29-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw200.14"},{"key":"bibr30-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.549"},{"key":"bibr31-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000698"},{"key":"bibr32-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz155.057"},{"key":"bibr33-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100093"},{"key":"bibr34-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01794-8"},{"key":"bibr35-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e15516"},{"key":"bibr36-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz246.098"},{"key":"bibr37-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0643"},{"key":"bibr38-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30425-4"},{"key":"bibr39-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2850-4"},{"key":"bibr40-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx261.329"},{"key":"bibr41-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3686-5"},{"key":"bibr42-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa243"},{"key":"bibr43-17588359221146137","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6533"},{"key":"bibr44-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.71"},{"key":"bibr45-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4036"},{"key":"bibr46-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0573"},{"key":"bibr47-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5063-5"},{"key":"bibr48-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e15019"},{"key":"bibr49-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw370.60"},{"key":"bibr50-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.564"},{"key":"bibr51-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4014601"},{"key":"bibr52-17588359221146137","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-020-03571-5"},{"key":"bibr53-17588359221146137","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.4.2453"},{"key":"bibr54-17588359221146137","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1238"},{"key":"bibr55-17588359221146137","unstructured":"ClinicalTrials.gov. Phase III study of trifluridine\/tipiracil in combination with bevacizumab vs trifluridine\/tipiracil single agent in patients with refractory metastatic colorectal cancer (SUNLIGHT), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04737187 (2022, accessed 3 June 2022)."},{"key":"bibr56-17588359221146137","unstructured":"Drug combination meets survival endpoint in phase III pivotal trial involving participants with refractory metastatic colorectal cancer [press release]\n                      . Paris, France: Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd. 2022."}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221146137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359221146137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221146137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:28:03Z","timestamp":1777588083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359221146137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":56,"alternative-id":["10.1177\/17588359221146137"],"URL":"https:\/\/doi.org\/10.1177\/17588359221146137","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17588359221146137"}}